Showing results (191-200 of 386) with videos related to

Sort By:
Pageof 39
JAMA Oncology|June 30, 2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical TrialsGeorgina V Long, Jeffrey S Weber, James Larkin, et al.
Blood|September 13, 2017
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphomaChristopher D Carey, Daniel Gusenleitner, Mikel Lipschitz, et al.
International Journal of Radiation Oncology, Biology, Physics|September 19, 2018
The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint InhibitorsLuke R G Pike, Andrew Bang, Brandon A Mahal, et al.
Cancer Research Communications|March 2, 2023
Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized LeukoplakiaGlenn J Hanna, Alessandro Villa, Nikhil Mistry, et al.
Cancer Research Communications|March 6, 2023
Correction: Comprehensive Immunoprofiling of High-risk Oral Proliferative and Localized LeukoplakiaGlenn J Hanna, Alessandro Villa, Nikhil Mistry, et al.
Cancer Cell|February 11, 2025
Genomic mediators of acquired resistance to immunotherapy in metastatic melanomaJulia Schiantarelli, Mouadh Benamar, Jihye Park, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 11, 2003
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destructionJan C Schmollinger, Robert H Vonderheide, Kara M Hoar, et al.
Cancer Immunology Research|August 14, 2021
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced MelanomaF Stephen Hodi, Jedd D Wolchok, Dirk Schadendorf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or LymphomasFunda Meric-Bernstam, Randy F Sweis, F Stephen Hodi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2021
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid TumorsMatthew D Hellmann, Nicoletta Bivi, Boris Calderon, et al.
Pageof 39